Abstract: A conduit locking system includes a first cylindrical conduit having a male and female portion. The female portion includes an engagement protrusion that is radially disposed on an outer surface, and an inner surface that is configured to engage an outer surface of a male portion of a second cylindrical conduit to define a continuous fluid passageway. The conduit locking system comprises an annular band having a tensioner and is configured to engage the male portion of the second cylindrical conduit. The annular band may also comprise a plurality of fingers disposed radially about the annular band. The plurality of fingers may be configured to engage the engagement protrusion of the female portion of the first cylindrical conduit. The conduit locking system is manipulatable between an unclamped position to a clamped position.

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Abstract: Provided herein are methods of treating cancer with a combination of an anti glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR)-antibody and an antibody that binds colony stimulating factor 1 receptor (CSF1R) or with a combination of an anti-GITR antibody and an antibody that binds programmed cell death protein 1 (PD-1).

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

Abstract: The invention provides improved compositions for adoptive cell therapies for cancers that express ROR1.

Abstract: Methods of identifying and using SLAMF1 antagonists are provided.

Abstract: A genus of erythropoietin (Epo) receptor agonists having unique structural, biochemical, and physiological characteristics has been discovered and is referred to herein as Erythropoietin Receptor extended Duration Limited Agonist (EREDLA).

Abstract: Methods of treating a fibrosacroma using flt-3 ligand are disclosed, as well as methods of increasing the number of dendritic cells in a patient having a fibrosarcoma.

Abstract: The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization.

Abstract: Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants. When flt3-L is used and/or administered in combination with other reactive agents, e.g. CD40 binding proteins, 4-1BBL or antibodies reactive with 4-1BB, CD30 ligand antagonists, RANKL, and/or interferon alpha the combination further enhances immune responses and the effectiveness of vaccine adjuvants.

Abstract: This invention relates to methods for treating rheumatoid arthritis (RA) by administering one or more agents that specifically target LIR-2, LIR-3 and LIR-7. Results disclosed herein indicate that these three LIRs may participate in regulating the activation of leukocytes that infiltrate synovial tissue. Thus, inflammation in the joints of RA patients can be ameliorated by administering agents that modulate expression or function of LIR-2 and/or LIR-3 and/or LIR-7 to reduce or eliminate the activation of monocytes or macrophages present in inflamed joints, or to reduce their recruitment to the site of inflammation. This can be accomplished by modulating LIR-7, which transmits a stimulatory signal, and/or by modulating LIR-2 and/or LIR-3, which when triggered exert an inhibitory effect, or by concurrently modulating two or all three of these LIRs.

Abstract: An electrical circuit material having a conductive layer disposed a substrate, wherein the substrate comprises an organic or inorganic polymer comprising a covalently bound polyhedral silsesquioxane (POSS). The substrate may further comprise an additional dispersed POSS, any other fillers including fibrous webs. Use of covalently bound POSS allows for flame retardancy in compositions having acceptable dielectric constants and dissipation factors.

Abstract: Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants. When flt3-L is used and/or administered in combination with other reactive agents, e.g. CD40 binding proteins, 4-1BBL or antibodies reactive with 4-1BB, CD30 ligand antagonists, RANKL, and/or interferon alpha the combination further enhances immune responses and the effectiveness of vaccine adjuvants.

Abstract: Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants. When flt3-L is used and/or administered in combination with other reactive agents, e.g. CD40 binding proteins, 4-1BBL or antibodies reactive with 4-1BB, CD30 ligand antagonists, RANKL, and/or interferon alpha the combination further enhances immune responses and the effectiveness of vaccine adjuvants.

Abstract: The invention concerns a process for the alkylation of at least one isoaffin selected from the group formed by isobutane and isopentane by at least one olefin containing 2 to 6 carbon atoms per molecule in the presence of a liquid acid catalyst, the process comprising mixing a feed comprising the olefin to be converted with an effluent comprising a major portion of isoparaffin in a first mixing zone, and forming an emulsion of said catalyst in a hydrocarbon effluent comprising a major portion of isoparaffin in an emulsifying zone, said effluent constituting the continuous phase of the emulsion thus formed, then mixing a major portion of the emulsion of acid in hydrocarbon effluent with a major portion of the diluted feed comprising the olefin in a second mixing zone, followed by carrying out the majority of the reaction in a reaction zone which is supplied by the major portion of said mixture.